【摘要】 司维拉姆和碳酸镧都是治疗终末期肾脏病患者高磷血症的新型非含钙磷结合剂。本文通过建立对中国透析患者高磷血症的治疗药物的经济学评价模型,比较这两种非含钙磷结合剂的经济性,为终末期肾脏病高磷血症患者磷结合剂的选择提供指导依据。文章包括对2016年1月发表在《卫生与医学经济学(Journal of Health&Medical Economics)》杂志上的文章"司维拉姆与碳酸镧治疗中国终末期肾脏病患者高磷血症的最小成本分析"的中文摘译和特邀药物经济学专家的点评。更多还原

【Abstract】 Sevelamer and lanthanum are both new non-calcium based phosphate binders in treating hyperphosphatemia among patients with endstage renal disease. This article compares the economics of these two non-calcium based phosphate binders based on health economic model of drugs in treating hyperphosphatemia for dialysis patients in China and provides supporting evidence on the selection of phosphate binders for hyperphosphatemia among patients with end-stage renal disease. This article includes the Chinese translated summary of "Cost-minimization Analysis between Sevelamer and Lanthanum in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China" [Journal of Health & Medical Economics, 2016, 2:1-6], which was published in January 2016 and expert opinion by invited pharmacoeconomic expert.更多还原